OPK Opko Health Inc.

2.81
+0.07  (+3%)
Previous Close 2.74
Open 2.74
Price To Book 0.97
Market Cap 1729784136
Shares 615,581,543
Volume 3,181,838
Short Ratio
Av. Daily Volume 5,748,563

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data due 1Q 2019.
OPK88003
Obesity and diabetes
Phase 2a trial planned for 2H 2018.
OPK88002
Pruritus in Stage 5 CKD patients undergoing dialysis
Phase 2a trial planned for 2H 2018.
OPK88001
Dravet Syndrome
Phase 2b trial to be initiated 2H 2017.
TT701 (selective androgen receptor modulator)
Benign Prostatic Hyperplasia (BPH)
Phase 2b trial suspension announced January 31, 2019.
OPK88004
Benign Prostatic Hyperplasia (BPH)
Phase 2 trial initiation announced September 4, 2018. Data from first cohort due 2019.
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP
Adults - growth hormone deficiency
Phase 3 completion of enrollment announced August 3, 2018.
hGH-CTP
Children - growth hormone deficiency
Announced June 21 2016 FDA Approval
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4
Phase 2 ongoing as of September 2017.
Factor VIIa-CTP
Hemophilia
Phase 3 to be initiated 1H 2018.
Fermagate Tablets
hyperphosphatemia in CKD patients on chronic hemodialysis
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV

Latest News

  1. Research Report Identifies Cognizant Technology Solutions, OPKO Health, MedEquities Realty Trust, AXT, Red Robin Gourmet Burgers, and Dorian LPG with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  2. See what the IHS Markit Score report has to say about OPKO Health Inc.
  3. Why Glu Mobile, Opko Health, and Church & Dwight Slumped Today
  4. Why Opko Health Is Tanking Today
  5. OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes
  6. The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results
  7. Johnson Fistel, LLP Announces Investigations of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. and Uxin Limited; Investors Encouraged to Contact Firm
  8. OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes
  9. Opko gets FDA OK for fingerstick test, seeks reversal on non-coverage ruling
  10. OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer
  11. OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator
  12. Future Non-Coverage Determination for 4Kscore Test Posted by Novitas
  13. Today's Research Reports on Trending Tickers: OPKO Health and Endo International
  14. BioReference Laboratories Supports Federal Employees Amidst Government Shutdown
  15. Here's Why Investors Should Bet on Abiomed (ABMD) Stock Now
  16. Varian Medical's (VAR) ProBeam Compact Picked by Biopolis
  17. Weekly CEO Buys Highlight
  18. Insiders Roundup: Stryker Corp, OPKO Health